MX2022015677A - Metodos para tratar la alergia usando anticuerpos anti-bet v 1. - Google Patents

Metodos para tratar la alergia usando anticuerpos anti-bet v 1.

Info

Publication number
MX2022015677A
MX2022015677A MX2022015677A MX2022015677A MX2022015677A MX 2022015677 A MX2022015677 A MX 2022015677A MX 2022015677 A MX2022015677 A MX 2022015677A MX 2022015677 A MX2022015677 A MX 2022015677A MX 2022015677 A MX2022015677 A MX 2022015677A
Authority
MX
Mexico
Prior art keywords
bet
antibodies
methods
treat allergy
antigen
Prior art date
Application number
MX2022015677A
Other languages
English (en)
Spanish (es)
Inventor
Jamie M Orengo
Amanda Atanasio
Lorah Perlee
Gary Herman
Meagan P O''brien
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022015677A publication Critical patent/MX2022015677A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
MX2022015677A 2020-07-01 2021-06-30 Metodos para tratar la alergia usando anticuerpos anti-bet v 1. MX2022015677A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047126P 2020-07-01 2020-07-01
US202063129253P 2020-12-22 2020-12-22
PCT/US2021/039945 WO2022006305A1 (en) 2020-07-01 2021-06-30 Methods of treating allergy using anti-bet v 1 antibodies

Publications (1)

Publication Number Publication Date
MX2022015677A true MX2022015677A (es) 2023-02-22

Family

ID=77168400

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015677A MX2022015677A (es) 2020-07-01 2021-06-30 Metodos para tratar la alergia usando anticuerpos anti-bet v 1.

Country Status (12)

Country Link
US (2) US11897945B2 (https=)
EP (1) EP4175986A1 (https=)
JP (1) JP2023531968A (https=)
KR (1) KR20230030573A (https=)
CN (1) CN115698059A (https=)
AU (1) AU2021300129A1 (https=)
BR (1) BR112022026279A2 (https=)
CA (1) CA3177918A1 (https=)
CL (1) CL2022003744A1 (https=)
IL (1) IL299207A (https=)
MX (1) MX2022015677A (https=)
WO (1) WO2022006305A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298034B2 (en) * 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
CA3177918A1 (en) 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
WO2024251358A1 (en) * 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010194A2 (de) 1992-10-27 1994-05-11 Biomay Produktions- Und Handelsgesellschaft M.B.H. MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES)
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1219299T4 (da) 2000-12-28 2011-02-14 Biomay Ag Allergivacciner og fremstilling deraf
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US10935554B2 (en) 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
IL298034B2 (en) 2017-06-01 2024-05-01 Regeneron Pharma Antibodies against BET V 1 and methods of using them
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
CA3177918A1 (en) 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
US20250263471A1 (en) 2024-01-30 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Also Published As

Publication number Publication date
CL2022003744A1 (es) 2023-06-02
JP2023531968A (ja) 2023-07-26
US20240209074A1 (en) 2024-06-27
US12583914B2 (en) 2026-03-24
IL299207A (en) 2023-02-01
AU2021300129A1 (en) 2022-12-08
CA3177918A1 (en) 2022-01-06
EP4175986A1 (en) 2023-05-10
WO2022006305A1 (en) 2022-01-06
BR112022026279A2 (pt) 2023-02-14
US20220002394A1 (en) 2022-01-06
CN115698059A (zh) 2023-02-03
KR20230030573A (ko) 2023-03-06
US11897945B2 (en) 2024-02-13

Similar Documents

Publication Publication Date Title
MX2022015677A (es) Metodos para tratar la alergia usando anticuerpos anti-bet v 1.
MX2022001156A (es) Anticuerpos que se fijan a gprc5d.
EA033072B1 (ru) Применение антител к семафорину 4d для лечения болезни хантингтона
BR112014008764A2 (pt) composições para o tratamento de artrite reumatóide e métodos de seu uso
EA202192606A1 (ru) Антитела к пироглутамат--амилоиду и их применение
EA201692192A1 (ru) СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
CR11243A (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
EA201891284A1 (ru) Композиции антител против cgrp и их применение
EA202191666A1 (ru) Антитела к il-27 и их применение
MX2020009037A (es) Anticuerpos de b7-h4 y métodos para usarlos.
BR112022019892A2 (pt) Métodos para tratar e/ou retardar a progressão de uma doença ou lesão e para monitorar o tratamento de um indivíduo
EA202091747A1 (ru) Составы антитела b7-h4
CO2020013833A2 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
AR107893A1 (es) TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
MX2025003476A (es) Anticuerpos anti-il-27 y usos de los mismos
EA201590720A8 (ru) АНТИ-Flt-1-АНТИТЕЛА В ЛЕЧЕНИИ МЫШЕЧНОЙ ДИСТРОФИИ ДЮШЕНА
BR112023023453A2 (pt) Anticorpo anti-tigit ou um fragmento de ligação ao antígeno deste e composições farmacêuticas compreendendo o referido anticorpo ou fragmento de ligação ao antígeno
MX2024008933A (es) Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares.
WO2023288204A8 (en) Diagnostics for porphyromonas gingivalis
MX2022004164A (es) Anticuerpos anti-flt-1 para tratar displasia broncopulmonar.
BR112022009265A2 (pt) Método de tratamento do câncer e método para aumentar, potencializar ou estimular uma resposta ou função imune
BR112022012093A2 (pt) Anticorpos contra integrina alfa 11 beta 1
MX2019001970A (es) Anticuerpo o un fragmento de union a antigeno del mismo, capaz de unirse a un receptor humano de interleucina-6.